Testosterone intramuscular


Brand Name(s):Testosterone enantate, Testosterone undecanoate (Nebido), Sustanon

Indication:Testosterone replacement therapy for male hypogonadism when testosterone deficiency has been diagnosed by an endocrinologist and confirmed by clinical features and biochemical tests



Review Date:Feb-25

SPC has been updated to advise that testosterone should be used with caution in patients with thrombophilia or risk factors for venous thromboembolism as there have been post-marketing studies and reports of thrombotic events in these patients during testosterone therapy

Initiation must only be made by an endocrinologist on diagnosis of male hypogonadism when testosterone deficiency has been confirmed by clinical features and biochemical tests.

Drug must be initiated and titrated to stable dosage by endocrinologist before GPs take over prescribing responsibility. Once medical condition and drug dosage is stable, there is no specific requirement for ongoing monitoring to be completed by GPs

All ongoing monitoring, including Testosterone levels, FBC, prostate exam, Lipid profile, LFT’s will be completed by endocrinology at intervals defined by the consultant.

Any dosage adjustments required will be completed by the endocrinologist and a letter will be sent to the GP informing them of this change

Dosages will be prescribed in accordance with the Summary of Product Characteristics

Doncaster & Bassetlaw Area Prescribing Committee
DBHFT Endocrinology
November 2010